Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2017 02:30 ET | Source: Active Biotech

Active Biotech: Interim report January - March 2017

Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting...
April 12, 2017 07:30 ET | Source: Active Biotech

Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma

Lund 12 April 2017 - Active Biotech AB (Nasdaq Stockholm:ACTI) announces today that Active Biotech has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its...
April 12, 2017 07:30 ET | Source: Active Biotech

Active Biotech: FDA beviljar särläkemedelsstatus för tasquinimod för behandling av multipelt myelom

Lund 12 april 2017 - Active Biotech AB (Nasdaq Stockholm:ACTI) meddelar i dag att Active Biotech har beviljats särläkemedelstatus av FDA (U.S. Food and Drug Administration) för tasquinimod, för...
February 16, 2017 02:30 ET | Source: Active Biotech

Active Biotech AB Bokslutsrapport januari - december 2016

Laquinimod De kliniska studierna CONCERTO, ARPEGGIO och LEGATO-HD fortgår enligt plan Studieresultat från den registreringsgrundande kliniska fas 3-studien CONCERTO i relapserande remitterande...
February 16, 2017 02:30 ET | Source: Active Biotech

Active Biotech AB Year-end report January - December 2016

Laquinimod The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting...
January 09, 2017 07:00 ET | Source: Active Biotech

The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma

Lund January 9, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) announces today that the European Patent Office has decided to grant Active Biotech's patent application covering tasquinimod for...
January 09, 2017 07:00 ET | Source: Active Biotech

Det europeiska patentverket beviljar patent för tasquinimod för behandling av multipelt myelom

Lund den 9 januari, 2017 - Active Biotech AB (Nasdag Stockholm: ACTI) meddelar att det Europeiska Patentverket har beslutat att bevilja Active Biotechs patentansökan som skyddar tasquinimod för...
December 30, 2016 02:30 ET | Source: Active Biotech

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue. Today, the last trading day of the month, there are in total 96,824,320 shares and...
December 30, 2016 02:30 ET | Source: Active Biotech

Antal aktier och röster i Active Biotech

Antalet aktier och röster i Active Biotech har förändrats på grund av den nyligen genomförda företrädesemissionen. Idag, den sista handelsdagen i månaden, finns totalt 96 824 320 aktier och...
December 12, 2016 11:31 ET | Source: Active Biotech

Active Biotechs nyemission genomförd

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, JAPAN ELLER KANADA ELLER I NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION AV DETTA...